PE20210177A1 - Inhibidores de cd73 - Google Patents

Inhibidores de cd73

Info

Publication number
PE20210177A1
PE20210177A1 PE2020001302A PE2020001302A PE20210177A1 PE 20210177 A1 PE20210177 A1 PE 20210177A1 PE 2020001302 A PE2020001302 A PE 2020001302A PE 2020001302 A PE2020001302 A PE 2020001302A PE 20210177 A1 PE20210177 A1 PE 20210177A1
Authority
PE
Peru
Prior art keywords
compound
nucleotidase
pyridazin
gem
dione
Prior art date
Application number
PE2020001302A
Other languages
English (en)
Inventor
Robert Dean Dally
Paredes Maria Cristina Garcia
Ii Lawrence Joseph Heinz
Jennifer Marie Howell
Frank George Njoroge
Yan Wang
Genshi Zhao
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of PE20210177A1 publication Critical patent/PE20210177A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente invencion se refiere a un compuesto de formula (I); en donde, n es 0-3; R1 es -H, -F, -gem-difluoro, -gem-dimetilo, -C1-4 alquilo, -CHF2, -CHF2CH3 o -CH2CH2F; y R2 se selecciona de -H, -CH3, -F, -Cl, -CN, o -OCH3 o sales aceptables desde el punto de vista farmaceutico. Un compuesto seleccionado es 5-[5]-[2-cicloalquil]-6-piridazin-3-il]-1Hpirimidin-2,4-diona; 5-[5-[(1S,2R)-2-isopropilciclopropil]-6-metil-piridazin-3-il]-1H-pirimidin-2,4-diona. Dicho compuesto inhibe la actividad de CD73 (enzima 5'-nucleotidasa o ecto-5'nucleotidasa) y son utiles en el tratamiento contra el cancer.
PE2020001302A 2018-03-01 2019-02-22 Inhibidores de cd73 PE20210177A1 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862636978P 2018-03-01 2018-03-01
US201862775553P 2018-12-05 2018-12-05
PCT/US2019/019074 WO2019168744A1 (en) 2018-03-01 2019-02-22 Cd73 inhibitors

Publications (1)

Publication Number Publication Date
PE20210177A1 true PE20210177A1 (es) 2021-01-29

Family

ID=65686120

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2020001302A PE20210177A1 (es) 2018-03-01 2019-02-22 Inhibidores de cd73

Country Status (33)

Country Link
US (1) US11028074B2 (es)
EP (1) EP3759096B1 (es)
JP (1) JP6794560B2 (es)
KR (1) KR20200116965A (es)
CN (1) CN111819173B (es)
AU (1) AU2019228473B2 (es)
BR (1) BR112020016066A2 (es)
CA (1) CA3092661C (es)
CL (1) CL2020002158A1 (es)
CO (1) CO2020010191A2 (es)
CR (1) CR20200376A (es)
CY (1) CY1125145T1 (es)
DK (1) DK3759096T3 (es)
DO (1) DOP2020000148A (es)
EC (1) ECSP20052897A (es)
ES (1) ES2909701T3 (es)
HR (1) HRP20220459T1 (es)
IL (1) IL277006B2 (es)
JO (1) JOP20200209A1 (es)
LT (1) LT3759096T (es)
MA (1) MA52413A (es)
MX (1) MX2020009115A (es)
PE (1) PE20210177A1 (es)
PH (1) PH12020551464A1 (es)
PL (1) PL3759096T3 (es)
PT (1) PT3759096T (es)
RS (1) RS63073B1 (es)
SG (1) SG11202008366RA (es)
SI (1) SI3759096T1 (es)
TW (1) TWI702954B (es)
UA (1) UA123890C2 (es)
WO (1) WO2019168744A1 (es)
ZA (1) ZA202004805B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7292501B2 (ja) * 2019-08-29 2023-06-16 イーライ リリー アンド カンパニー Cd73阻害剤の結晶形態
US20210198239A1 (en) * 2019-12-06 2021-07-01 Plexxikon Inc. Compounds and methods for cd73 modulation and indications therefor
US11807626B2 (en) 2020-04-23 2023-11-07 Opna Bio SA Compounds and methods for CD73 modulation and indications therefor
CN115698009A (zh) * 2020-05-01 2023-02-03 吉利德科学公司 抑制cd73的2,4-二氧代嘧啶化合物
CN115702150A (zh) * 2020-07-07 2023-02-14 贝达药业股份有限公司 Cd73抑制剂及其在医药上的应用
CA3191829A1 (en) 2020-09-08 2022-03-17 Hao Wu Cd73 inhibitor and application thereof in medicine
CN114315839A (zh) * 2020-09-30 2022-04-12 武汉人福创新药物研发中心有限公司 嘧啶二酮类化合物及其用途
WO2022090711A1 (en) 2020-10-26 2022-05-05 AdoRx Therapeutics Limited Compounds as cd73 inhibitors
CN114437038A (zh) * 2020-11-05 2022-05-06 武汉人福创新药物研发中心有限公司 哒嗪炔烃类化合物及其用途
CA3197340A1 (en) 2020-11-05 2022-05-12 Xuejun Zhang Cd73 inhibitor and use thereof
CN116134029A (zh) * 2020-12-10 2023-05-16 上海翰森生物医药科技有限公司 氧代氮环类衍生物调节剂、其制备方法和应用
WO2022195499A1 (en) * 2021-03-19 2022-09-22 Aurigene Discovery Technologies Limited Substituted pyridazine compounds as cd73 inhibitors
CN118201941A (zh) 2021-10-29 2024-06-14 吉利德科学公司 Cd73化合物
WO2023169327A1 (zh) * 2022-03-07 2023-09-14 贝达药业股份有限公司 一种哒嗪类衍生物的晶型、制备方法及其应用
WO2023201267A1 (en) 2022-04-13 2023-10-19 Gilead Sciences, Inc. Combination therapy for treating trop-2 expressing cancers
WO2024006929A1 (en) * 2022-07-01 2024-01-04 Gilead Sciences, Inc. Cd73 compounds
WO2024013206A1 (en) * 2022-07-14 2024-01-18 F. Hoffmann-La Roche Ag Heterocycle compounds for the treatment of cancer

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200870404A1 (ru) 2006-04-03 2009-04-28 Глэксо Груп Лимитед Производные азабицикло[3.1.0.]гексила в качестве модуляторов рецепторов допамина d3
EP1860113A1 (en) * 2006-05-24 2007-11-28 Rheinische Friedrich-Wilhelms-Universität Bonn Ectonucleotidase inhibitors
AR105654A1 (es) 2015-08-24 2017-10-25 Lilly Co Eli Anticuerpos pd-l1 (ligando 1 de muerte celular programada)
CN114395005A (zh) * 2016-01-08 2022-04-26 艾库斯生物科学有限公司 胞外5’-核苷酸酶的调节剂及其用途
WO2017153952A1 (en) 2016-03-10 2017-09-14 Glaxosmithkline Intellectual Property Development Limited 5-sulfamoyl-2-hydroxybenzamide derivatives

Also Published As

Publication number Publication date
DOP2020000148A (es) 2020-09-15
EP3759096B1 (en) 2022-02-16
IL277006A (en) 2020-10-29
AU2019228473B2 (en) 2021-02-25
KR20200116965A (ko) 2020-10-13
IL277006B (en) 2022-11-01
MX2020009115A (es) 2022-11-15
WO2019168744A1 (en) 2019-09-06
JP6794560B2 (ja) 2020-12-02
BR112020016066A2 (pt) 2020-12-08
CN111819173A (zh) 2020-10-23
HRP20220459T1 (hr) 2022-05-27
CA3092661C (en) 2022-07-12
DK3759096T3 (en) 2022-03-07
CL2020002158A1 (es) 2020-11-13
ECSP20052897A (es) 2020-09-30
RS63073B1 (sr) 2022-04-29
PH12020551464A1 (en) 2021-09-01
CR20200376A (es) 2020-10-23
PT3759096T (pt) 2022-03-30
CO2020010191A2 (es) 2020-08-31
SG11202008366RA (en) 2020-09-29
JP2020517655A (ja) 2020-06-18
CN111819173B (zh) 2023-06-06
PL3759096T3 (pl) 2022-05-09
TW201945002A (zh) 2019-12-01
JOP20200209A1 (ar) 2020-08-30
ZA202004805B (en) 2022-01-26
CA3092661A1 (en) 2019-09-06
MA52413A (fr) 2021-01-06
IL277006B2 (en) 2023-03-01
TWI702954B (zh) 2020-09-01
AU2019228473A1 (en) 2020-08-20
CY1125145T1 (el) 2024-02-16
EP3759096A1 (en) 2021-01-06
SI3759096T1 (sl) 2022-07-29
US20210002257A1 (en) 2021-01-07
US11028074B2 (en) 2021-06-08
LT3759096T (lt) 2022-04-11
UA123890C2 (uk) 2021-06-16
ES2909701T3 (es) 2022-05-10

Similar Documents

Publication Publication Date Title
PE20210177A1 (es) Inhibidores de cd73
MX2021006026A (es) Pirimidina y derivado heterociclico de nitrogeno de cinco miembros, metodo de preparacion y usos medicos de los mismos.
PE20141855A1 (es) Benzotienilo-pirrolotriazinas disustituidas y sus usos
PH12020551305A1 (en) Pharmaceutical Compounds
MX2021013110A (es) Compuestos heterociclicos como inhibidores de la cinasa ret.
EA201691428A1 (ru) Бициклические гетероциклические производные в качестве ингибиторов irak4
PE20170189A1 (es) Nuevos derivados de pirazolo pirimidina y su uso como inhibidores de malt1
TN2014000128A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
PE20170520A1 (es) Compuestos de heteroarilo utiles como inhibidores de enzima activadora de sumo
PH12014500947B1 (en) 1,2,5-oxadiazoles as inhibitors of indoleamine 2,3-dioxygenase
ATE427941T1 (de) Thiazolderivate mit vap-1-hemmender wirkung
EA201270570A1 (ru) Комбинированная терапия раковых заболеваний с помощью соединений-ингибиторов hsp90
MA33745B1 (fr) Piperidines substituees qui accroissent l'activite de p53, et utilisation de ces composes
NI201300111A (es) Derivados de pirazoloespirocetona para uso como inhibidores de acetil-coa carboxilasa
PE20181144A1 (es) Derivados de heteroarilo como inhibidores de parp
MX2020008570A (es) Inhibidores de arginasa y sus metodos de uso.
EA200800302A1 (ru) Применение производных и аналогов тиазола при лечении рака
UY39261A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
RU2018102963A (ru) Производные анилинпиримидина и их применения
RU2011112684A (ru) АГЕНТ, СПОСОБСТВУЮЩИЙ РОСТУ ВОЛОС, СОДЕРЖАЩИЙ В КАЧЕСТВЕ АКТИВНОГО ИНГРЕДИЕНТА ПРОИЗВОДНОЕ 15,15-ДИФТОРПРОСТАГЛАНДИНА F2α
BR112022001922A2 (pt) Compostos de heteroarila de anel fundido como inibidores de ripk1
MX2008016358A (es) Derivados de tiazolil-urea como inhibidores de cinasa de fosfatidil-inositol-3.
PE20221630A1 (es) Derivado de amino arilo novedoso util como inhibidor de diacilglicerol aciltransferasa 2 y uso del mismo
WO2008101029A3 (en) Use of thiazole, oxazole and imidazole compounds for the treatment of sodium channel-mediated diseases or conditions
BR112021017710A2 (pt) Composto, composição farmacêutica, método de tratamento